 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
15 News |  |
- || INO-5150 / Inovio, rocakinogene sifuplasmid (INO-9012) / Inovio
Clinical, Journal: CD8 T Cells Impact Rising PSA in Biochemically Relapsed Cancer Patients Using Immunotherapy Targeting Tumor-Associated Antigens. (Pubmed Central) - Jun 8, 2021
Immunogenicity was observed in 76% (47/62) of patients by multiple assessments. Analysis indicated that CD38 and perforin co-positive CD8 T cell frequency correlated with attenuated PSA rise (p = 0.05, n = 50).
- INO-5150 / Inovio, INO-9012 / Inovio
Immunotherapy targeting PSA and PSMA in patients with biochemically recurrent prostate cancer expands antigen-specific T cell receptor repertoire in a PhI/II trial (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_4376;
Patients with immune reactivity by flow cytometry were more likely to have a higher frequency of PSA/PSMA specific TCRs that expanded >10 fold over their pre-treatment value; however patients without immune reactivity also demonstrated expansion in TCRs. These data suggest that INO-5150 induced PSA/PSMA specific T cells and that TCR sequencing is a valuable tool for assessment of immune responses induced by immunotherapy that does not bias towards a specific T cell function.
- ||| INO-5150 / Inovio, rocakinogene sifuplasmid (INO-9012) / Inovio
Trial completion, Trial primary completion date, Combination therapy: Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer (clinicaltrials.gov) - Dec 26, 2017
P1, N=62, Completed, Sponsor: Inovio Pharmaceuticals
These data suggest that INO-5150 induced PSA/PSMA specific T cells and that TCR sequencing is a valuable tool for assessment of immune responses induced by immunotherapy that does not bias towards a specific T cell function. Active, not recruiting --> Completed | Trial primary completion date: Feb 2017 --> Dec 2017
- || INO-5150 / Inovio, rocakinogene sifuplasmid (INO-9012) / Inovio
Enrollment closed, Combination therapy: Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer (clinicaltrials.gov) - Jul 13, 2016
P1, N=60, Active, not recruiting, Sponsor: Inovio Pharmaceuticals
Active, not recruiting --> Completed | Trial primary completion date: Feb 2017 --> Dec 2017 Recruiting --> Active, not recruiting
- ||| INO-5150 / Inovio, rocakinogene sifuplasmid (INO-9012) / Inovio
New P1 trial, Combination therapy: Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer (clinicaltrials.gov) - Aug 3, 2015
P1, N=60, Recruiting, Sponsor: Inovio Pharmaceuticals